Barlet J P, Coxam V, Davicco M J
Métabolisme Minéral, INRA, Centre de Clermont-Theix.
Presse Med. 1995 Nov 25;24(36):1703-6.
Parathyroid hypertensive factor (PHF) is a newly discovered circulating factor that has been implicated in some forms of hypertension. Such an involvement has been established in several animal models and in hypertensive patients. PHF originates from the parathyroid glands. This explains why hypertensive individuals often have high levels of circulating parathyroid hormone (PTH), which is itself hypotensive. This would reflect the activity of the parathyroid glands, which would produce PHF concomitantly with PTH. The mechanism of action of PHF involves an increase in calcium-channel activity in vascular smooth muscle cells. The opening of these channels would lead to increase calcium entry into these cells, resulting in increased sensitivity to other vasoconstrictors. PHF level explains why a high calcium diet may be effective in lowering blood pressure in patients who respond to calcium-channels blockers: dietary calcium might inhibit the production of PHF (and PTH), whereas calcium-channels blockers would inhibit PHF at its target site.
甲状旁腺高血压因子（PHF）是一种新发现的循环因子，与某些类型的高血压有关。这种关联已在多种动物模型和高血压患者中得到证实。PHF起源于甲状旁腺。这就解释了为什么高血压个体通常循环甲状旁腺激素（PTH）水平较高，而PTH本身具有降压作用。这反映了甲状旁腺的活动，甲状旁腺会在产生PTH的同时产生PHF。PHF的作用机制涉及血管平滑肌细胞中钙通道活性的增加。这些通道的开放会导致更多的钙进入这些细胞，从而增加对其他血管收缩剂的敏感性。PHF水平解释了为什么高钙饮食可能对那些对钙通道阻滞剂有反应的患者降低血压有效：膳食钙可能会抑制PHF（和PTH）的产生，而钙通道阻滞剂会在其靶位点抑制PHF。
